Production of Recombinant Proteins from the Secretions of Lucilia Sericata Larvae for Wound Healing

Masoumeh Bagheri^*
*Correspondence: Masoumeh Bagheri, Department of Medical Entomology, School of Health, Shiraz University of Medical Sciences, Iran, Email:

Keywords

Maggot therapy. Recombinant Protein. Wound healing

Introduction

Today, due to the increasing number of accidents, burns, diabetes, aging, etc., the chronic wounds caused by them are also increasing. Treatment of diabetic foot ulcers and other chronic ulcers has high economic costs on the patient and health care [1,2].

Wounds have become resistant to a wide range of antibiotics. Maggot therapy is a useful, effective and controlled method using sterilized larvae Lucilia sericata to treat a variety of acute and chronic wounds. It can be used as an alternative, classic and controlled method instead of other wound healing methods In this method, larvae can accelerate wound healing by moving on the wound and cleaning and disinfecting it [3]. But many patients refuse to do this method, because they has aversion and phobia to Lucilia sericata, And they do not feel good about the movement of living beings on the wounds of their bodies.

The use of recombinant proteins to treat many diseases has been considered by biotechnology researchers, so that today we see the use of recombinant pharmaceutical products, instead of the previous chemical drugs [4]. These proteins have a specific function and because they originate from the body's biological molecules. Many prokaryotic and eukaryotic cells are used as hosts for the production of these proteins, advantages to using a system that best preserves the properties of natural protein, and should be able to maintain high production, high purification, short time, maximum protein biological activity.

Lucelia sericata larvae degrade dead wound tissue, produce neurogenesis, and subsequently wound healing by producing a variety of wound-degrading enzymes and proteins [5]. Larval secretions include a variety of proteolytic enzymes(leucine, carboxypeptidase, aminopeptidases, collagenases,…) , growth factors, antimicrobial peptides, anti-inflammatory and other unknown compounds in wound healing [6]. Due to the development of biological science and the production of recombinant proteins, miraculous peptide materials of larval secretions can be produced as recombinant proteins. And replaced them with chemical drugs and antibiotics to treat wounds [7].

In recent years, recombinant compounds have been produced from the secretions of Lucilia sericata larvae. But the number of recombinant proteins produced from the secretions of Lucelia sericata larvae is low [7].

Discussion

Maggot therapy has benefits such as wound cleansing, disinfection, as well as accelerating wound healing and being replaced by traditional wound healing methods [8] However, for reasons such as direct and prolonged contact of insect larvae with wounds and causing fear and phobia, people do not show much satisfaction and interest in using this method and avoid this treatment. Therefore, the production and synthesis of many compounds Bioavailability in blowflies, such as enzymes and proteins effective in wound healing, is being produced as recombinant proteins using chemical and genetic engineering methods. In recent years, however, recombinant compounds (chymotrypsin-like enzyme) have been produced from the secretions of Lucilia sericata larvae. But only a few of them have been effective in wound healing [9]. There are gaps in studies on the identification and production of effective proteins of Lucilia sericata larvae and their use in the treatment of wounds. The process of producing recombinant protein, like other processes, has a number of limitations, such as the length and hardness of the process, having sufficient proficiency in the process, and the high cost of materials, etc., which may receive less attention from scientists [7,10].

References

1. Bryant, Ruth, and Denise Nix. Acute and chronic wounds: current management concepts. Elsevier Health Sciences, 2015.
2. Al-Gharibi, Koukab A., Sajana Sharstha, and Maria A. Al-Faras. "Cost-effectiveness of wound care: a concept analysis." Sultan Qaboos University Medical Journal 18, no. 4 (2018): e433.
3. Bonn, Dorothy. "Maggot therapy: an alternative for wound infection." The Lancet 356, no. 9236 (2000): 1174.
4. Dingermann, Theo. "Recombinant therapeutic proteins: production platforms and challenges." Biotechnology Journal: Healthcare Nutrition Technology 3, no. 1 (2008): 90-97.
5. Choudhary, Vijayata, Mukesh Choudhary, Sunanda Pandey, Vandip D. Chauhan, and J. J. Hasnani. "Maggot debridement therapy as primary tool to treat chronic wound of animals." Veterinary world 9, no. 4 (2016): 403.
6. Chambers, L., S. Woodrow, A. P. Brown, P. D. Harris, D. Phillips, M. Hall, J. C. T. Church, and D. I. Pritchard. "Degradation of extracellular matrix components by defined proteinases from the greenbottle larva Lucilia sericata used for the clinical debridement of non‐healing wounds." British Journal of Dermatology 148, no. 1 (2003): 14-23.
7. Yakovlev, A. Yu, A. A. Kruglikova, and S. I. Chernysh. "Calliphoridae flies in medical biotechnology." Entomological Review 99, no. 3 (2019): 292-301.
8. Stojadinovic, Alexander, Jay W. Carlson, Gregory S. Schultz, Thomas A. Davis, and Eric A. Elster. "Topical advances in wound care." Gynecologic oncology 111, no. 2 (2008): S70-S80.
9. Pöppel, Anne-Kathrin, Mareike Kahl, Andre Baumann, Jochen Wiesner, Anke Gökçen, Annika Beckert, Klaus T. Preissner, Andreas Vilcinskas, and Zdeněk Franta. "A Jonah-like chymotrypsin from the therapeutic maggot Lucilia sericata plays a role in wound debridement and coagulation." Insect biochemistry and molecular biology 70 (2016): 138-147.
10. Gopal, Gopal Jee, and Awanish Kumar. "Strategies for the production of recombinant protein in Escherichia coli." The protein journal 32, no. 6 (2013): 419-425.